Immunological Relationship Between the Fast-Acting Plasminogen Activator Inhibitors from Plasma, Blood Platelets and Endothelial Cells Demonstrated with a Monoclonal Antibody Against an Inhibitor from Placenta

M Philips; Anne-Grethe Juul; S Thorsen; J Selmer; J Zeuthen

doi:10.1055/s-0038-1661524

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1986; 55(02): 213-217
DOI: 10.1055/s-0038-1661524

Original Article

Schattauer GmbH Stuttgart

Immunological Relationship Between the Fast-Acting Plasminogen Activator Inhibitors from Plasma, Blood Platelets and Endothelial Cells Demonstrated with a Monoclonal Antibody Against an Inhibitor from Placenta

M Philips

¹The Department of Clinical Chemistry, University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark

,

Anne-Grethe Juul

¹The Department of Clinical Chemistry, University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark

,

S Thorsen

¹The Department of Clinical Chemistry, University of Copenhagen, Hvidovre Hospital, Hvidovre, Denmark

,

J Selmer

²The NOVO BioLabs, Novo Industri A/S, Bagsvaerd, Denmark

,

J Zeuthen

²The NOVO BioLabs, Novo Industri A/S, Bagsvaerd, Denmark

› Author Affiliations

Abstract

PDF Download

Summary

Two plasminogen activator inhibitors (I and II) were demonstrated in human placenta. The complex between inhibitor I and tissue-type plasminogen activator was purified by immunoadsorption to solid-phase anti-activator antibodies. The purified complex (M_r 95.000) was used for immunization of mice and subsequent production of monoclonal antibodies. One antibody (F37), which reacted with both free and complex-bound inhibitor I, was used for further study by a method involving binding of the antibody to protein A-Sepharose, immunoadsorp-tion of antigen and analysis of the resulting supernatant by SDS-polyacrylamide gel electrophoresis and enzymography. The analysis showed that F37 reacted with the fast-acting plasminogen activator inhibitors recently demonstrated in plasma, blood platelets and endothelial cells, indicating that these inhibitors and inhibitor I share a common epitope. Inhibitor II did not react with F37. Inhibitor II is identical to the placenta inhibitor previously described by others. It reacted selectively with polyclonal antibodies against that inhibitor.

Key words

Plasminogen activator inhibitor - Endothelial cells - Plasma - Blood platelets - Monoclonal antibodies

PDF (1282 kb)

References

References
1 Nagamine Y, Pearson D, Altus MS, Reich E. cDNA and gene nucleotide sequence of porcine plasminogen activator. Nucleic Acids Res 1984; 12: 9525-9541
2 Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci USA 1984; 81: 5355-5359
3 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
4 Weimer W, Stibbe J, van Seyen AJ, Billiau A, De Somer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981; 2: 1018-1020
5 Sobel BE, Geltman EM, Tiefenbrunn AJ, Jaffe AS, Spadaro JJ, Ter-Pogossian MM, Collen D, Ludbrook PA. Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase. Circulation 1984; 69: 983-990
6 Reich E. Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis. In: Molecular Basis of Biological Degradative Processes Berlin RD, Herrman H, Lepow IH, Tanzer JM. (Eds) Academic Press; New York, San Francisco, London: 1978: 155-169
7 Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Danø K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982; 24: 6410-6415
8 Wun TC, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem 1982; 7262-7268
9 Wallen P, Pohl G, Bergsdorf N, Ranby M, Ny T, Jomvall H. Purification and characterization of a melanoma cell plasminogen activator. Eur J Biochem 1983; 132: 681-686
10 Andreasen PA, Nielsen LS, Grøndahl-Hansen J, Skriver L, Zeuthen J, Stephens RW, Danø K. Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J 1984; 3: 51-56
11 Heussen C, Joubert F, Dowdle EB. Purification of human tissue plasminogen activator with Erythrina trypsin inhibitor. J Biol Chem 1984; 259: 11635-11638
12 Ichinose A, Kisiel W, Fujikawa K. Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes. FEBS Lett 1984; 175: 412-418
13 Holmberg L, Lecander I, Persson B, Astedt B. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. Biochim Biophys Acta 1978; 544: 128-137
14 Åstedt B, Lecander I, Brodin T, Lundblad A, Löw K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen. Thromb Haemostas 1985; 53: 122-125
15 Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: Evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804-6808
16 van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-14921
17 Philips M, Juul A-G, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 99-110
18 Sprengers ED, Verheijen JH, van Hinsbergh V WM, Emeis JJ. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta 1984; 801: 163-170
19 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
20 Juhan-Vague I, Moerman B, de Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
21 Kruithof E KO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
22 Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta 1984; 802: 111-118
23 Verheijen JH, Chang G TG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
24 Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-3647
25 Kruithof E KO, Ransijn A, Tran-Thang C, Bachmann F. Characteristics of a fast acting inhibitor of plasminogen activator in human plasma. Thromb Haemostas 1983; 50: 193 (Abstr)
26 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-1472
27 Scott RW, Bergman BL, Bajpai A, Hersh RT, Rodriguez H, Jones BN, Barreda C, Watts S, Baker JB. Protease nexin. Properties and a modified purification procedure. J Biol Chem 1985; 260: 7029-7034
28 Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456
29 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
30 Selmer J, Brender J, Suenson E, Thorsen S. Characterization of mono-chain tissue-type plasminogen activator (t-PA) purified by immunoadsorption to a monoclonal antibody. In Clinical Aspects of Fibrinolysis and Thrombolysis Jespersen J, Kluft C, Korsgaard O. (Eds) South Jutland University Press; Esbjerg, Denmark: 1983: 43-44
31 Weber K, Osborn M. Proteins and sodium dodecyl sulphate; molecular weight determination on polyacrylamide gels and related procedures. In: The Proteins Neurath H, Hill RL. (Eds) Academic Press; New York, San Francisco, London: vol. 1 1975: 179-223
32 Morrissey JH. Silver stain for proteins in polyacrylamide gels: A modified procedure with enhanced uniform sensitivity. Analyt Biochemistry 1981; 117: 307-310
33 Sandbjerg HansenM, Clemmensen I. Partial purification and characterization of a new fast-acting plasmin inhibitor from human platelets. Biochem J 1980; 187: 173-180
Larsen FS, Selmer JS, Hertz JB. Purification of Bordetella pertussis antigens using monoclonal antibodies. Acta Path Microbiol Immunol Scand Sect C 1984; 92: 271-277
35 Taggart RT, Samloff IM. Stable antibody-producing murine hybridomas. Science 1983; 219: 1228-1230
36 Åstedt B, Bladh B, Christensen U, Lecander I. Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates. Scand J Clin Invest 1985; 45: 429-435